Page last updated: 2024-10-19

niacinamide and Keloid

niacinamide has been researched along with Keloid in 1 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Keloid: A sharply elevated, irregularly shaped, progressively enlarging scar resulting from formation of excessive amounts of collagen in the dermis during connective tissue repair. It is differentiated from a hypertrophic scar (CICATRIX, HYPERTROPHIC) in that the former does not spread to surrounding tissues.

Research Excerpts

ExcerptRelevanceReference
"Sorafenib is a promising agent for the treatment of keloids and hypertrophic scars."5.43Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways. ( Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W, 2016)
"Sorafenib is a promising agent for the treatment of keloids and hypertrophic scars."1.43Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways. ( Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, W1
Qu, M1
Xu, L1
Wu, X1
Gao, Z1
Gu, T1
Zhang, W1
Ding, X1
Liu, W1
Chen, YL1

Other Studies

1 other study available for niacinamide and Keloid

ArticleYear
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
    Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:10

    Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans;

2016